1 Gallagher W M, Lynch I, Allen L T, et al. Molecular basis of cell-biomaterial interaction: insights gained from transcriptomic and proteomic studies. Biomaterials, 2006, 27: 5871–5882？？
[2]
2 Ratner B D, Bryant S J. Biomaterials: where we have been and where we are going. Annu Rev Biomed Eng, 2004, 6: 41–75？？
[3]
3 Chen A M, Scott M D. Current and future applications of immunological attenuation via pegylation of cells and tissue. Bio Drugs, 2001, 15:833–847
[4]
4 Chen A M, Scott M D. Comparative analysis of polymer and linker chemistries on the efficacy of immunocamouflage of murine leukocytes. Artif Cells Blood Substit Immobil Biotechnol, 2006, 34: 305–322？？
[5]
5 Scott M D, Murad K L, Koumpouras F, et al. Chemical camouflage of antigenic determinants: stealth erythrocytes. Proc Natl Acad Sci USA,1997, 94: 7566–7571？？
[6]
6 Sutton T C, Scott M D. The effect of grafted methoxypoly(ethylene glycol) chain length on the inhibition of respiratory syncytial virus (RSV) infection and proliferation. Biomaterials, 2010, 31: 4223–4230？？
[7]
7 Laemmli U K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 1970, 227: 680–685？？
[8]
8 Ross P L, Huang Y N, Marchese J N, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics, 2004, 3: 1154–1169？？
[9]
9 Vroman L. Effect of absorbed proteins on the wettability of hydrophilic and hydrophobic solids. Nature, 1962, 196: 476–477？？
[10]
10 Horbett T A. Mass action effects on competitive adsorption of fibrinogen from hemoglobin solutions and from plasma. Thromb Haemost,1984, 51: 174–181
[11]
11 Harris J M. Introduction to bioetchnical and biomedical applications of poly(ethylene glycol). In: Harris M J, ed. Topics in Applied Chemistry. New York: Plenum Press, 1992. 1–14？？
[12]
12 Andrade J D. Interfacial phenomena and biomaterials. Med Instrum, 1973, 7: 110–119
[13]
13 Bradley A J, Murad K L, Regan K L, et al. Biophysical consequences of linker chemistry and polymer size on stealth erythrocytes: size does matter. Biochim Biophys Acta, 2002, 1561: 147–158？？
[14]
14 Murad K L, Mahany K L, Brugnara C, et al. Structural and functional consequences of antigenic modulation of red blood cells with methoxypoly(ethylene glycol). Blood, 1999, 93: 2121–2127
[15]
15 Bradley A J, Test S T, Murad K L, et al. Interactions of IgM ABO antibodies and complement with methoxy-PEG-modified human RBCs. Transfusion, 2001, 41: 1225–1233？？
[16]
16 Scott M D, Chen A M. Beyond the red cell: pegylation of other blood cells and tissues. Transfus Clin Biol, 2004, 11: 40–46？？
[17]
17 Bradley A J, Scott M D. Separation and purification of methoxypoly(ethylene glycol) grafted red blood cells via two-phase partitioning. J Chromatogr B Analyt Technol Biomed Life Sci, 2004, 807: 163–168？？
[18]
18 Bradley A J, Scott M D. Immune complex binding by immunocamouflaged
[19]
[poly(ethylene glycol)-grafted] erythrocytes. Am J Hematol,2007, 82: 970–975？？
[20]
19 Murad K L, Gosselin E J, Eaton J W, et al. Stealth cells: prevention of major histocompatibility complex class II-mediated T-cell activation by cell surface modification. Blood, 1999, 94: 2135–2141
[21]
20 Chen A M, Scott M D. Immunocamouflage: prevention of transfusion-induced graft-versus-host disease via polymer grafting of donor cells. J Biomed Mater Res A, 2003, 67: 626–636
[22]
21 Scott M D, Murad K L. Cellular camouflage: fooling the immune system with polymers. Curr Pharm Des, 1998, 4: 423–438
[23]
22 McCoy L L, Scott M D. Broad-spectrum antiviral porphylaxis: inhibition of viral infection by polymer grafting with methoxypoly(ethylene glycol). In: Torrence P F, ed. Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats. New York: John Wiley & Sons, Inc,2005. 379–395？？
[24]
23 Szleifer I. Protein adsorption on surfaces with grafted polymers: a theoretical approach. Biophys J, 1997, 72: 595–612？？
[25]
24 Hermans J. Excluded-volume theory of polymer-protein interactions based on polymer chain statistics. J Chem Phys, 1982, 77: 2193–2203？？
[26]
25 Brooks D E, Haynes C A, Hritcu D, et al. Size exclusion chromatography does not require pores. Proc Natl Acad Sci USA, 2000, 97:7064–7067？？
[27]
26 Yasmeen D, Ellerson J R, Dorrington K J, et al. The structure and function of immunoglobulin domains. IV. The distribution of some effector functions among the Cgamma2 and Cgamma3 homology regions of human immunoglobulin G1. J Immunol, 1976, 116: 518–526
[28]
27 Colomb M, Porter R R. Characterization of a plasmin-digest fragment of rabbit immunoglobulin gamma that binds antigen and complement. Biochem J, 1975, 145: 177–183
[29]
28 Reid K B. Complete amino acid sequences of the three collagen-like regions present in subcomponent C1q of the first component of human complement. Biochem J, 1979, 179: 367–371
[30]
29 Lawler J, Duquette M, Urry L, et al. The evolution of the thrombospondin gene family. J Mol Evol, 1993, 36: 509–516？？
[31]
30 Miyakis S, Giannakopoulos B, Krilis S A. Beta 2 glycoprotein I-function in health and disease. Thromb Res, 2004, 114: 335–346？？
[32]
31 Brighton T A, Hogg P J, Dai Y P, et al. Beta 2-glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant. Br J Haematol,1996, 93: 185–194？？
[33]
32 Doyen V, Rubio M, Braun D, et al. Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation. J Exp Med,2003, 198: 1277–1283？？
[34]
33 Li Z, He L, Wilson K, et al. Thrombospondin-1 inhibits TCR-mediated T lymphocyte early activation. J Immunol, 2001, 166: 2427–2436
[35]
34 Fleischer J, Grage-Griebenow E, Kasper B, et al. Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. J Immunol, 2002, 169: 770–777
[36]
35 Ehlert J E, Ludwig A, Grimm T A, et al. Down-regulation of neutrophil functions by the ELR(+) CXC chemokine platelet basic protein. Blood, 2000, 96: 2965–2972
